iwCLL 2023

2023 iwCLL Program Agenda

**AGENDA topics and times subject to change** As of 04/20/23
Friday, October 6
7:30 AM
YIM Continental Breakfast
8:00 AM
Young Investigator Meeting
6:00 PM
iwCLL Welcome Reception
Saturday, October 7, 2023
7:15 AM
Continental Breakfast
8:15 AM
Welcome and Introductions
Jennifer Brown, MD, PhD
8:30 AM
Honoring the Past: In Memoriam and 20 Years of iwCLL
Session 1: Integrative Aspects of Genomics
Session Co-Chair: Christopher Oakes, MD, PhD
8:40 AM
Multiomic Integration in CLL
Cynthia K. Hahn, MD
8:55 AM
Whole-Genome Analysis of CLL and Interplay of Coding, Non-Coding, Transcriptome and Epigenetic Events
Pauline Robbe, PhD
9:10 AM
Genomics of Richter’s Transformation: Part I
Ferran Nadeu, PhD
9:20 AM
Genomics of Richter’s Transformation: Part II
Erin Parry, MD, PhD
9:30 AM
Commentary and Consensus Regarding the Genomics of Richter’s Transformation
Ferran Nadeu, PhD and Erin Parry, PhD
9:40 AM
Panel Discussion With Interactivity and Audience Q&A
9:50 AM
Oral and Poster Abstracts
10:10 AM
Morning Break
Session 2: Proteomics and Metabolism of CLL
Session Co-Chair: Catherine Wu, MD
10:35 AM
Proteogenomic Characterization of CLL and Drug Response/Resistance
Sascha Dietrich, MD
10:50 AM
CLL Proteomics and Immunoproteomics
Catherine Wu, MD
11:05 AM
Cancer Metabolism
TBD
11:20 AM
Panel Discussion With Interactivity and Audience Q&A
11:35 AM
Oral and Poster Abstracts
12:05 PM
Lunch
12:55 PM
Industry Supported Symposium
Session 3: Microenvironment and Pre-Clinical Immunotherapies
Session Co-Chair: Adrian Wiestner, MD, PhD
1:55 PM
Anti-Tumor Immunity in the Lymphoid Microenvironment
Martina Seiffert, PhD
2:10 PM
The Tumor Supportive Microenvironment of CLL
Jerome Paggetti, PhD
2:25 PM
Modeling the Tumor Microenvironment of CLL
Christina Scielzo, PhD
2:35 PM
The Tumor Microenvironment and Genetic Heterogeneity of CLL
Clare Sun, MD
2:45 PM
Panel Discussion With Interactivity and Audience Q&A
3:05 PM
Oral and Poster Abstracts
3:25 PM
Afternoon Break
3:50 PM
Keynote
Session 4: Debate and Roundtable – How Do We Define Success in CLL?
Session Co-Chair: John Seymour, MBBS, PhD
4:20 PM
Multiparty “Statement of Perspective”
Michele Nadeem Baker
Danielle Brander, MD
Barbara Eichhorst, MD
Carsten Niemann, MD, PhD
Andrew Roberts, PhD
William Wierda, MD, PhD
4:55 PM
Panel Discussion With Interactivity and Audience Q&A
5:30 PM
Oral and Poster Abstracts
5:50 PM
Adjourn
End of Day 1
Sunday, October 8
7:00 AM
Industry Supported Symposium
7:15 AM
Continental Breakfast
Session 5: Optimizing Initial Therapy of CLL
Session Co-Chair: Matthew Davids, MD, MMSc
8:15 AM
The Role Today of Continuous BTK Inhibitors
Kerry Rogers, MD
8:30 AM
Updated Perspective on Time-Limited Venetoclax + Obintuzumab
Othman Al-Sawaf, MD
8:45 AM
Current and Future Use of BTKi + BCL-2i Combinations
Nitin Jain, MD
9:00 AM
Panel Discussion With Interactivity and Audience Q&A
9:15 AM
Trials in Progress
9:35 AM
Oral and Poster Abstracts
9:55 AM
Morning Break
10:20 AM
Industry Supported Symposium
Session 6: Mechanisms of Resistance
Session Co-Chair: Jennifer Woyach, MD
11:20 AM
Resistance to Covalent BTKi
Adrien Wiestner, MD, PhD
11:35 AM
Resistance to Non-Covalent BTKi
Varsha Gandhi, MD
11:50 AM
Resistance to BCL2i

Rachel Thijssen, Phd

12:05 PM

Panel Discussion With Interactivity and Audience Q&A

12:20 PM
Oral and Poster Abstracts

12:40 PM

Lunch

1:30 PM

Industry Supported Symposium
Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL
Session Co-Chair: Arnon Kater, MD, PhD
2:30 PM
BTK Degraders – From Bench To Bedside
Alexey Danilov, MD, PhD
2:40 PM
Novel Inducers of Apoptosis
Deepa Sampath, PhD
2:50 PM
How to Overcome T-Cell Dysfunction: Bispecifics
Arnon Kater, MD, PhD
3:00 PM
How to Overcome T-Cell Dysfunction: Cellular Therapies
Jos Melenhorst, PhD
3:10 PM
Panel Discussion with Interactivity and Audience Q&A
3:25 PM
Trials in Progress
3:45 PM
Oral and Poster Abstracts
4:05 PM
Binet/Rai Medal Presentation

4:15 PM

Adjourn
Wine & Cheese Poster Session and Reception

End of Day 2
Monday, October 9
7:00 AM
Industry Supported Symposium
7:15 AM
Continental Breakfast
Session 8: Richter’s Transformation – From Biology to Clinic
Session Co-Chair: Inhye Ahn, MD
8:15 AM
In Vivo Modeling of CLL Transformation
Silvia Deaglio, MD, PhD
8:25 AM
In Vivo Modeling of CLL Transformation: Multiplex In Vivo CRISPR Editing
Elisa Ten Hacken, PhD
8:35 AM
In Vivo Modeling of CLL Transformation: TP53 and CDKN2a/b Model
Dimitar Efremov, MD, PhD
8:45 AM
Panel Discussion on In Vivo Modeling
8:55 AM
Chemoimmunotherapy and BCR-Targeted Agents for Richter’s Transformation
Sameer Parikh, MBBS
9:05 AM
Investigational Therapies for Richter’s Transformation: Bispecifics
Philip Thompson, BA, BSW, MSW, PhD
9:15 AM
Investigational Therapies for Richter’s Transformation: Cellular Therapies
Tanya Siddiqi, MD
9:25 AM
Panel Discussion with Interactivity and Audience Q&A
9:35 AM
Oral and Poster Abstracts
9:55 AM
Morning Break
Session 9: Immunodeficiency and Infections in Patients with CLL
Session Co-Chair: Carsten Niemann, MD, PhD
10:20 AM
CLL Vaccine Responsiveness
Chris Pleyer, MD
10:35 AM
What Can We Learn from COVID About Immune Dysfunction and Risk of Infections in CLL?
Yair Herishanu, MD
10:50 AM
General Management of CLL patients from a Vaccine and Prophylaxis Standpoint
Carolyn Owen
11:05 AM
Panel Discussion with Interactivity and Audience Q&A
11:20 AM
Oral and Poster Abstracts
11:40 AM
Industry Supported Symposium
12:40 PM
LUNCH
Session 10: Global Perspective on CLL Management – Real World Data and Patient Experiences
Session Co-Chair: Anna Schuh, MD, PhD
1:30 PM
The Impact of the War on Management of Patients with CLL in Ukraine: What can the iwCLL do to Mitigate Impact in Short and Longer Term
Iryna Kryachok,, Prof., PhD
1:40 PM
Managing Patients with CLL from Different Socio-Economic Backgrounds in Argentina
Miguel Pavlovsky, MD
1:50PM
Update on the iwCLL Capacity Building Pilot Program in Tanzania
William Frank Mawalla, MD
2:00 PM
Challenges of Diagnosis and Management of Patients with CLL in South Korea
Ja Min Byun, MD, PhD
2:10 PM
Trial Updates from China
Shenmiao Yang, MD
2:20 PM
Global Survey Results from the CLL Advocates Network
Nick York

2:30 PM

Panel Discussion With Interactivity and Audience Q&A

2:50 PM

Afternoon Break
Session 11: Past, Present, and Future of CLL
Session Co-Chair: Jennifer R. Brown, MD, PhD

3:15 PM

TBD

3:30 PM

Remaining Unmet Needs in the Care of CLL
TBD

3:45 PM

Role of the iwCLL Going Forward
TBD

4:00 PM

Panel Discussion With Interactivity and Audience Q&A

4:20 PM

Closing Comments/iwCLL 2023 Awards/2025 Announcement

Jennifer R. Brown, MD, PhD

4:35 PM

Close of Workshop